-$0.65 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter
Analysts predict that Epizyme, Inc. (NASDAQ:EPZM) will report earnings of ($0.65) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Epizyme’s earnings. The lowest EPS estimate is ($0.75) and the highest is ($0.57). Epizyme posted earnings per share of ($0.42) in the same quarter last year, which suggests a negative year-over-year growth rate of 54.8%. The business is expected to issue its next earnings results on Thursday, November 2nd.
On average, analysts expect that Epizyme will report full-year earnings of ($2.34) per share for the current year, with EPS estimates ranging from ($2.54) to ($2.20). For the next financial year, analysts forecast that the business will report earnings of ($2.52) per share, with EPS estimates ranging from ($3.11) to ($2.18). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Epizyme.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.08. The business had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $3.95 million. During the same quarter in the previous year, the company posted ($0.49) EPS. The company’s revenue was up 2027.7% compared to the same quarter last year.
Several research firms recently commented on EPZM. BidaskClub cut Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Leerink Swann reiterated an “outperform” rating and issued a $28.00 price target (down previously from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research note on Tuesday, September 19th. Cann reiterated a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research note on Tuesday, September 19th. Finally, Jefferies Group LLC began coverage on Epizyme in a research note on Wednesday, September 20th. They issued a “buy” rating and a $23.00 price target on the stock. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $23.33.
ILLEGAL ACTIVITY WARNING: “-$0.65 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/10/0-65-earnings-per-share-expected-for-epizyme-inc-epzm-this-quarter.html.
Epizyme (NASDAQ EPZM) traded down 0.28% on Tuesday, hitting $17.95. The stock had a trading volume of 360,891 shares. The firm’s market cap is $1.05 billion. The company’s 50 day moving average is $17.50 and its 200 day moving average is $15.44. Epizyme has a 12-month low of $8.38 and a 12-month high of $20.45.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $15.68, for a total value of $235,200.00. Following the completion of the sale, the insider now directly owns 22,228 shares of the company’s stock, valued at $348,535.04. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David M. Mott acquired 200,000 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was purchased at an average cost of $15.25 per share, with a total value of $3,050,000.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at $91,500. The disclosure for this purchase can be found here. Over the last three months, insiders sold 45,000 shares of company stock valued at $688,950. 25.20% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in EPZM. Legal & General Group Plc grew its holdings in shares of Epizyme by 8.9% during the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in shares of Epizyme during the first quarter valued at approximately $175,000. BB&T Securities LLC bought a new position in shares of Epizyme during the second quarter valued at approximately $181,000. Trexquant Investment LP bought a new position in shares of Epizyme during the second quarter valued at approximately $184,000. Finally, SG Americas Securities LLC grew its holdings in shares of Epizyme by 83.3% during the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 6,072 shares during the last quarter. 72.23% of the stock is owned by hedge funds and other institutional investors.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.